Insmed (NSM) Doses First Patient in ARIKACE Phase 2
Insmed Incorporated (Nasdaq: INSM), announced that the first patient has been dosed in the Company's U.S. phase 2 clinical study of ARIKACE® (liposomal amikacin for inhalation) in patients with non-tuberculous mycobacterial (NTM) lung disease entitled TARGET-NTM (Treatment with ARIKACE to Realize Greater Efficacy Trial).
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- StemCells (STEM) Reports First Transplant in Phase II Pathway Study
- Tetraphase Pharmaceuticals (TTPH) PT Lifted to $41 at Baird on Bullish IGNITE-1 Data
- RedHill Biopharma (RDHL) Anounces Acquisition of MAP Bacterium Detection Technology
Create E-mail Alert Related CategoriesCorporate News, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!